

31 March 2016

The Companies Office  
Australian Securities Exchange Limited  
Sydney

---

## Bioxyne Announces 2016 Goals

**Bioxyne Limited** (or the Company) (**ASX:BXN**) yesterday released its updated Corporate Presentation. The Presentation summarises the business plan and strategy of the Company over the next 12 months to grow sales from its *Lactobacillus fermentum* PCC®.

This is the culmination of planning for the past year. Probiotics based products in the Health and Wellness dietary supplement market is a high growth sector.

In brief, the Company aims to:

- Focus on its lead asset, *Lactobacillus fermentum* PCC®, a probiotic that has been demonstrated to boost immune health as a result of its interaction with the gastrointestinal tract;
- Launch two PCC® based products in Australia in 2016 – Progastrim and proTract for Atopic Dermatitis. Bioxyne currently holds the TGA registration for both these products;
- Undertake registration of PCC® in China to open up the significant potential for sales of PCC based products in the Chinese market;
- Undertake further clinical studies to further support and boost the sales and marketing efforts of our major partners Nu-Skin and Christian Hansen;
- Develop new markets for PCC® based products.

This program of activities will be funded from existing cash reserves. The newly appointed Executive Director, Dr Peter French, has carriage of these responsibilities, and, working with the Board, has already achieved first steps for all of them.

The Board will report progress against these aims.

**ENDS**

## **About Bioxyne**

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne's focus is currently on the company's probiotic business and proprietary product *Lactobacillus fermentum* PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

For more information please contact:

**Tony Ho**

**Non-executive chairman**

**Bioxyne Limited**

+61 417 345 839

**Jarrold White**

**Company Secretary | Chief Financial Officer**

**Bioxyne Limited**

+61 8296 0000